Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Cancer ; 143(5): 1134-1142, 2018 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-29569716

RESUMEN

Osteosarcoma is a primary malignant bone tumor that has a high potential to metastasize to lungs. Little is known about the mechanisms underlying the dissemination of OS cancer cells to lungs. We performed whole exome sequencing of 13 OS primary tumors, with matched lung metastases and normal tissues. Phylogenetic analyses revealed that lung metastatic tumors often harbor clones that are nonexistent or rare in the matched primary OS tumors. Spatially and temporally separated lung metastases were from parallel seeding events with a polyphyletic pattern. Loss of TP53 or RB1 is among the early events during OS tumorigenesis, while loss of PTEN is involved at the later stages associated with lung metastases. Finally, KEAP1 was identified as a novel biomarker for increased metastatic risk. Patients whose primary tumors harbored KEAP1 amplification have significantly poorer lung-metastasis free survival. This finding was validated in two independent datasets. Further, in vitro experiments exhibited that KEAP1 depletion suppressed the invasion of OS cells. Our findings uncover the patterns of clonal evolution during OS progression and highlight KEAP1 as a novel candidate associated with the risk of lung metastasis in OS patients.


Asunto(s)
Biomarcadores de Tumor/genética , Neoplasias Óseas/patología , Evolución Clonal , Proteína 1 Asociada A ECH Tipo Kelch/genética , Neoplasias Pulmonares/secundario , Mutación , Osteosarcoma/patología , Neoplasias Óseas/genética , Progresión de la Enfermedad , Amplificación de Genes , Humanos , Neoplasias Pulmonares/genética , Osteosarcoma/genética , Fosfohidrolasa PTEN/genética , Pronóstico , Tasa de Supervivencia , Proteína p53 Supresora de Tumor/genética , Secuenciación del Exoma
2.
Bone Res ; 9(1): 7, 2021 Jan 29.
Artículo en Inglés | MEDLINE | ID: mdl-33514693

RESUMEN

Low back pain (LBP), as a leading cause of disability, is a common musculoskeletal disorder that results in major social and economic burdens. Recent research has identified inflammation and related signaling pathways as important factors in the onset and progression of disc degeneration, a significant contributor to LBP. Inflammatory mediators also play an indispensable role in discogenic LBP. The suppression of LBP is a primary goal of clinical practice but has not received enough attention in disc research studies. Here, an overview of the advances in inflammation-related pain in disc degeneration is provided, with a discussion on the role of inflammation in IVD degeneration and pain induction. Puncture models, mechanical models, and spontaneous models as the main animal models to study painful disc degeneration are discussed, and the underlying signaling pathways are summarized. Furthermore, potential drug candidates, either under laboratory investigation or undergoing clinical trials, to suppress discogenic LBP by eliminating inflammation are explored. We hope to attract more research interest to address inflammation and pain in IDD and contribute to promoting more translational research.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA